Long-term dasatinib findings support first-line use in CML

Final DASISION study findings confirm dasatinib to be an effective, long-term treatment for patients with a new diagnosis of chronic phase–chronic myeloid leukaemia.
Source: MedWire News - Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news